<DOC>
	<DOCNO>NCT00288444</DOCNO>
	<brief_summary>To determine molecular interaction tumor sample docetaxel lonafarnib .</brief_summary>
	<brief_title>Interaction Docetaxel Lonafarnib Patients With Advanced Cancer</brief_title>
	<detailed_description>1 . To determine safety toxicity intravenous docetaxel , administer weekly schedule ( 3 week 4 ) , combination oral lonafarnib , administer daily schedule , patient locally advance metastatic solid tumor malignancy refractory standard care . 2 . To determine pharmacokinetic interaction docetaxel lonafarnib . 3 . To determine molecular interaction peripheral blood mononuclear cell docetaxel lonafarnib</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>.1.1 Patient must pathologicallyconfirmed locally advanced metastatic solid tumor malignancy demonstrate refractory standard care , tumor accessible needle surgical biopsy . 3.1.2 Only patient determine minimal risk receive biopsy ( tumor location/accessibility well underlying patient comorbidities judge allow minimal risk biopsy radiologist/surgeon perform procedure ) eligible study . 3.1.3 Patient must ECOG performance status 2 less . 3.1.4 Patient must lifeexpectancy least 12 week . 3.1.5 Patient must adequate bone marrow function : WBC ≥ 3,000 cells/mm3 , ANC ≥ 1,500 cells/mm3 , platelet count ≥ 100,000/mm3 Hgb ≥ 9.0 g/dL . 3.1.6 Patient must adequate liver function : total bilirubin level ≤ 2.0 mg/dL ≤ ULN , albumin ≥ 2.5 g/dL . 3.1.7 Patient must adequate renal function : Transaminases/Alkaline phosphatase : AST ALT alkaline phosphatase must within range allow eligibility . This range define ≤ 2 x ULN . In determine eligibility , abnormal two ( AST ALT ) use . 3.1.8 Patient must receive three previous chemotherapy regimen ( prior chemotherapy may may contain taxane ) . 3.1.9 Patient must meet specified inform consent requirement . 3.1.10 Patient must age ≥ 18 year . 3.1.11 Women childbearing age must negative pregnancy test . 3.1.12 Men woman childbearing potential must willing consent use effective contraception treatment least 3 month thereafter . 3.1.13 Patient must ≤ Grade 1 neurotoxicity previous anticancer treatment cause . 3.1.14 Patient must adequate coagulation function : INR PTT ≤ 1.5 x ULN . 3.1.15 Patient must discontinue prior chemotherapy radiotherapy least 4 week prior registration . 3.1.16 Patient must discontinue use follow drug inducer inhibitor CYP3A4 least 2 day prior registration : ethinylestradiol , gestodene , itraconazole , ketoconazole , cimetidine , erythromycin , carbamazepine , high dose chronic steroid , phenobarbital , phenytoin , rifampin ( rifampcin ) , sulfinpyrazone . Patient must pathologicallyconfirmed 3.2.1 Patient receive three previous chemotherapy regimen . 3.2.2 Patient pregnant breast feeding . 3.2.3 Patient sign symptom acute infection require systemic therapy . 3.2.4 Patient exhibit confusion , disorientation , history major psychiatric illness may impair patient 's understanding informed consent . 3.2.5 Patient 's life expectancy le 12 week . 3.2.6 Patient &gt; Grade 1 neurotoxicity previous anticancer treatment significant neuropathy cause . 3.2.7 Patient require total parenteral nutrition lipid . 3.2.8 Inability swallow lonafarnib BID . 3.2.9 Patient history uncontrolled heart disease ( include clinically significant coronary artery disease , congestive heart failure symptomatic uncontrolled arrythmias ) . 3.2.10 Patient history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 . Symptoms include : reaction bronchospasm , generalize urticaria , systolic BP ≤ 80mm Hg , angioedema . 3.2.11 Use chronic steroid anticonvulsant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Advanced malignancy .</keyword>
</DOC>